MPNCo&D Program
| Friday, October 6, 2023 | |
| Hall C |
|
| Myeloproliferative Neoplasms (MPNCo&D) | |
| 09:15-10:45 | Session 1: Polycythemia Vera in 2023 and beyond |
| Moderators: Naveen Pemmaraju, USA; Claire Harrison, UK & Ruben Mesa, USA |
|
| Debate: Standard of care in PV | |
| 09:15-09:25 | Thrombosis/risk stratification in PV – aiming for a normal PBC: Mary Frances McMullin, UK |
| 09:25-09:35 | IFN in PV – with molecular monitoring: Jean-Jacques Kiladjian, France |
| 09:35-09:50 | PTG-300/Rusfertide: from bench to bedside – Hepcidin Mimetics in PV: Ronald Hoffman, USA |
| Debate: All PV patients should be treated | |
| 09:50-10:00 | Yes, including lower-risk: Tiziano Barbui, Italy |
| 10:00-10:10 | No, only higher risk: Ruben Mesa, USA |
| 10:10-10:25 | Should we still use HU for PV – can RUX go to the front line? Claire Harrison, UK |
| 10:25-10:45 | Roundtable discussion: All session faculty |
| 10:45-11:15 | Coffee Break |
| 11:15-12:45 | Session 2: Essential thrombocytosis – Can we do better? |
| Moderators: Claire Harrison, UK; Anna Godfrey, UK |
|
| 11:15-11:35 | Higher risk ET: state-of-the-art management in 2023: Claire Harrison, UK |
| 11:35-11:50 | What is my approach to triple negative thrombocytosis? Anna Godfrey, UK |
| 11:50-12:10 | Should all patients with ET have aspirin? Tiziano Barbui, Italy |
| 12:00-12:30 | CALR: role of immunotherapy as future directions/novel approaches: Bethan Psaila, UK |
| 12:30-12:45 | Roundtable discussion: All session faculty |
| 12:45-13:00 | Lunch Box Pick-up and Break |
| MPNCo&D Program Pause |
|
| 14:45-16:15 | Session 3: Myelofibrosis: current and novel approaches in a rapidly developing field |
| Moderators: Naveen Pemmaraju, USA; John Mascarenhas, USA |
|
| 14:45-15:00 | Pre-fibrotic MF: a new entity with special considerations: Paola Guglielmelli, Italy |
| 15:00-15:15 | Early/lower risk MF: treatment options and approach: Ruben Mesa, USA |
| 15:15-15:30 | Int/higher risk MF: current treatment options in 2023: John Mascarenhas, USA |
| 15:30-15:45 | Current data for combinations for JAKi naïve patients: Naveen Pemmaraju, USA |
| 15:45-16:00 | Clinical and molecular factors, biomarkers of MPN progression: current and future: Adam Mead, UK |
| 16:00-16:15 | Anemia in MF: an emerging area for novel approaches: Naveen Pemmaraju, USA |
| 16:15-16:30 | Coffee Break |
| 16:30-18:00 | Session 4: Treatment of high-risk MF |
| Moderators: Florian Heidel, Germany; John Mascarenhas, USA |
|
| 16:30-16:45 | How to define failure of JAKi: Florian Heidel, Germany |
| 16:45-17:00 | Current outcomes for transplantation in MF: Maria Robin, France |
| Debate: Future directions: Transplantation in MPN | |
| 17:00-17:10 | Transplant early before patients fail a JAKi: Donal McLornan, UK |
| 17:10-17:20 | Patients failing a JAKi can be salvaged without BMT: John Mascarenhas, USA |
| 17:20-17:35 | Novel agents in the clinic beyond JAKi: Raajit Rampal, USA |
| 17:35-18:00 | Roundtable discussion: All session faculty |
| Saturday, October 7, 2023 | |
| Hall C |
|
| Myeloproliferative Neoplasms (MPNCo&D) | |
| 09:00-10:45 | Session 5: AYA MPNs: pregnancy, thromboses and special considerations (ending at 10:45) |
| Moderators: Isabelle Plo, France; Ruben Mesa, USA |
|
| 09:00-09:15 | New data for thrombosis in MPN: Anna Falanga, Italy |
| 09:15-09:30 | Gastro-oncology: splanchnic vein thrombosis a primer for haematologists: David Patch, UK |
| 09:30-09:45 | Cardio-oncology: primer on intersection of cardio-oncology and MPNs: arrythmias, clots, anticoagulation and cardiac considerations: Michael Fradley, USA |
| 09:45-10:00 | Pregnancy, fertility and hormone therapy: state-of-the-art considerations: Susan Robinson, UK |
| 10:00-10:15 | Young patients with MPNs: unique considerations in thromboses: Jean-Christophe Ianotto, France |
| 10:15-10:30 | Latest update on inheritability and MPN: Isabelle Plo, France |
| 10:30-10:45 | Roundtable discussion: All session faculty |
| 10:30-11:00 | Coffee Break |
| 11:00-12:30 | Session 6: Rare MPNs – Focus on emerging subtypes |
| Moderators: Deepti Radia, UK; Andreas Reiter, Germany |
|
| 11:00-11:15 | Investigation and management of eosinophilia: Andreas Reiter, Germany |
| 11:15-11:30 | Aggressive SM: emerging therapy options: Deepti Radia, UK |
| 11:30-11:45 | Current management of CMML: Eric Solary, France |
| 11:45-12:00 | Investigation and management of congenital erythrocytosis: Mary Frances McMullin, UK |
| 12:00-12:30 | Roundtable discussion: All session faculty |
| 12:30-13:00 | Lunch Box Pick-up and Break |
| MPNCo&D Program Pause |
|
| 14:45-16:15 | Session 7: Current and future considerations in MPNs and rare hematologic malignancies: building innovative, sustainable programs across the world |
| Moderators: Naveen Pemmaraju, USA; Ruben Mesa, USA |
|
| 14:45-15:00 | What is patient advocacy? Jonathan Mathias, UK |
| 15:00-15:15 | Building MPN communities and the role of MPN advocates network: Werner Zinkand, Germany |
| 15:15-15:35 | Future directions in MPN: AI and MPN: Daniel Royston, UK |
| 15:35-15:55 | CHIP and MPNs: what have we learned from population studies in Denmark? Hans Hasselbalch, Denmark |
| 15:55-16:15 | Plenary lecture: MPNs and Targeting stem cells in MF: Past, Present and Future: Ronald Hoffman, USA |
| 16:15-16:30 | Coffee Break |
| 16:30-17:00 | IACH Closing Plenary Lecture in Hall A |